# Norgine GmbH

Company profile · SME (from the award notice)

- Legal form: GmbH
- Seat: Wettenberg, Germany

Based on the notices and sources Inteliwert covers; not a complete record. Last checked 29 September 2026.

## Identifiers

- Register entry: HRB 9522

As the covered sources state them.

## Track record in public tenders

Awards in the covered notices over the last 36 months, per CPV division.

| CPV division | Awards | Award value (excl. VAT) | Buyers | Repeat buyers | First award | Last award |
| --- | ---: | ---: | ---: | ---: | --- | --- |
| 33 Medical equipments, pharmaceuticals and personal care products | 1 | €1 | 1 | 0 | 29 September 2026 | 29 September 2026 |

Based on the notices and sources Inteliwert covers; not a complete record.

### Awards

- [Bekanntmachung vergebener Aufträge nach §130 a Abs. 8 SGB V und §130 c SGB V zu den Präparaten mit den Wirkstoffen Mavorixafor (Xolremdi) und Eisenmaltol (Feraccru)](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de)  
  Buyer: GWQ ServicePlus AG · Award value: €1 excl. VAT · Awarded: 29 September 2026 · CPV 33600000
- [Abschluss eines nicht-exklusiven Rabattvertrages gemäß §§ 130a Abs. 8, 130c Abs. 1 SGB V zwischen der IKK classic und der Norgine GmbH zu Xolremdi (R)](https://inteliwert.com/tender/opp_AXYERB5B1PRB2CGJANWXTRY3SY/abschluss-eines-nicht-exklusiven-rabattvertrages-gemaess-130a-abs-8-130c-abs-1-s)  
  Buyer: IKK classic · Award value: €1 excl. VAT · Awarded: 13 July 2026 · CPV 33600000

## Certifications and prequalification

No certification or prequalification found in the covered sources.

A certification missing here is unknown, not absent.

## Website and LinkedIn

Not found in the indexed notices.

## Open tenders that might fit

*Possible match based on public information*

Companies Inteliwert knows from its sources, not the whole market. Inteliwert does not judge eligibility, fit or chances.

- [Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta](https://inteliwert.com/tender/opp_K0S9DCPHW7XNMQ121EY84FQFN2/open-house-biologika-rabattvertraege-2026-27-follitropin-delta)  
  Open · SME (from the award notice) · Buyer: Techniker Krankenkasse · Deadline: 31 Aug 2028, 23:58 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/2037548d-47d4-4e5d-9fac-2fbf38c148be), Last checked 10 Nov 2026, 17:31 (UTC+01:00)
  - Won a contract in CPV group 336 (2026-09-29): [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
  - Seat in the same country as the place of performance: [Evidence](https://inteliwert.com/company/org_5XF8BQ5ZW1YBVFJ61XGHKYZKK9), checked 10 Nov 2026
  - 2 awards in this field in 36 months, from 2 buyers: [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
- [Open house Arzneimittelrabattverträge zum Wirkstoff Pridinol, ATC M03BX03](https://inteliwert.com/tender/opp_JQ324N5Y8FJ1XR7912TM9A6V77/open-house-arzneimittelrabattvertraege-zum-wirkstoff-pridinol-atc-m03bx03)  
  Open · SME (from the award notice) · Buyer: AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse · Deadline: 30 Jun 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/d0a4f77c-ca41-4231-bdb4-f67ad5747661), Last checked 10 Nov 2026, 09:30 (UTC+01:00)
  - Won a contract in CPV group 336 (2026-09-29): [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
  - Seat in the same country as the place of performance: [Evidence](https://inteliwert.com/company/org_5XF8BQ5ZW1YBVFJ61XGHKYZKK9), checked 10 Nov 2026
  - 2 awards in this field in 36 months, from 2 buyers: [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
- [Open house Arzneimittelrabattverträge zum Wirkstoff Natriumoxybat, ATC N07XX04](https://inteliwert.com/tender/opp_562AV918AD3460EF7NMMFYH9G8/open-house-arzneimittelrabattvertraege-zum-wirkstoff-natriumoxybat-atc-n07xx04)  
  Open · SME (from the award notice) · Buyer: AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse · Deadline: 30 Jun 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/ff1a52b0-3f84-4241-a978-4b3486c7e5c1), Last checked 10 Nov 2026, 09:30 (UTC+01:00)
  - Won a contract in CPV group 336 (2026-09-29): [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
  - Seat in the same country as the place of performance: [Evidence](https://inteliwert.com/company/org_5XF8BQ5ZW1YBVFJ61XGHKYZKK9), checked 10 Nov 2026
  - 2 awards in this field in 36 months, from 2 buyers: [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
- [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Tacrolimus, ATC L04AD02 für die Zeit 01.09.2026 - 31.08.2028](https://inteliwert.com/tender/opp_RJ2ABV76EPE592S5RQRTVDET7S/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi)  
  Open · SME (from the award notice) · Buyer: DAK-Gesundheit · Deadline: 5 Jul 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/2c829b35-d439-4150-9da8-fb52fe6331ad), Last checked 10 Nov 2026, 10:30 (UTC+01:00)
  - Won a contract in CPV group 336 (2026-09-29): [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
  - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_RJ2ABV76EPE592S5RQRTVDET7S/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 10 Nov 2026
  - 2 awards in this field in 36 months, from 2 buyers: [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
- [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Natalizumab (ausschließlich Darreichungsform ILO), ATC L04AA23 für die Zeit 01.09.2026 - 31.08.2028](https://inteliwert.com/tender/opp_0X36VER1BS4CJ6NYP1D6WSWW9M/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi)  
  Open · SME (from the award notice) · Buyer: DAK-Gesundheit · Deadline: 5 Jul 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/cebcb363-7cb4-4060-a79c-f1e8372d6fab), Last checked 10 Nov 2026, 10:30 (UTC+01:00)
  - Won a contract in CPV group 336 (2026-09-29): [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
  - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_0X36VER1BS4CJ6NYP1D6WSWW9M/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 10 Nov 2026
  - 2 awards in this field in 36 months, from 2 buyers: [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
- [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Emtricitabin + Rilpivirin + Tenofovir disoproxil fumarat, ATC J05AR08 für die Zeit 01.09.2026 - 31.08.2028](https://inteliwert.com/tender/opp_1TBX7K9XNMM7XN64W74V3W4T5F/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi)  
  Open · SME (from the award notice) · Buyer: DAK-Gesundheit · Deadline: 5 Jul 2028, 12:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/6aa4bfd3-5c5b-468c-93c6-c397c11f5de2), Last checked 10 Nov 2026, 10:30 (UTC+01:00)
  - Won a contract in CPV group 336 (2026-09-29): [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
  - The contract value is close to the values of its past awards: [Evidence](https://inteliwert.com/tender/opp_1TBX7K9XNMM7XN64W74V3W4T5F/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 10 Nov 2026
  - 2 awards in this field in 36 months, from 2 buyers: [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
- [Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)](https://inteliwert.com/tender/opp_63RWEWHGD43EJKAE0RZ379P62Y/abschluss-nicht-exkl-arzneimittel-rabattvereinb-nach-130a-abs-8-sgb-v-im-wege-ei)  
  Open · SME (from the award notice) · Buyer: AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen · Deadline: 30 Sept 2027, 23:58 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/ec6cf9bd-065e-45fd-a8b7-e1abe83a74b0), Last checked 10 Nov 2026, 16:30 (UTC+01:00)
  - Won a contract in CPV group 336 (2026-09-29): [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
  - Seat in the same country as the place of performance: [Evidence](https://inteliwert.com/company/org_5XF8BQ5ZW1YBVFJ61XGHKYZKK9), checked 10 Nov 2026
  - 2 awards in this field in 36 months, from 2 buyers: [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
- [Arzneimittel-Rabattverträge ab 01.09.2026 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens](https://inteliwert.com/tender/opp_34ACXCE3NDME4KVX9DX6K3S003/arzneimittel-rabattvertraege-ab-01-09-2026-zu-diversen-wirkstoffen-im-rahmen-ein)  
  Open · SME (from the award notice) · Buyer: AOK NordWest · Deadline: 1 Jul 2028, 17:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/59d00624-8c12-4222-aeff-bbab245237f0), Last checked 10 Nov 2026, 19:30 (UTC+01:00)
  - Won a contract in CPV group 336 (2026-09-29): [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
  - Seat in the same country as the place of performance: [Evidence](https://inteliwert.com/company/org_5XF8BQ5ZW1YBVFJ61XGHKYZKK9), checked 10 Nov 2026
  - 2 awards in this field in 36 months, from 2 buyers: [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
- [Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)](https://inteliwert.com/tender/opp_M03SCNB8G9PVV857HPXV71Y88Y/abschluss-nicht-exkl-arzneimittel-rabattvereinb-nach-130a-abs-8-sgb-v-im-wege-ei)  
  Open · SME (from the award notice) · Buyer: AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen · Deadline: 31 Aug 2028, 23:58 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/40d03459-68bf-4b36-92bd-b208463d1c31), Last checked 10 Nov 2026, 16:30 (UTC+01:00)
  - Won a contract in CPV group 336 (2026-09-29): [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
  - Seat in the same country as the place of performance: [Evidence](https://inteliwert.com/company/org_5XF8BQ5ZW1YBVFJ61XGHKYZKK9), checked 10 Nov 2026
  - 2 awards in this field in 36 months, from 2 buyers: [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
- [Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)](https://inteliwert.com/tender/opp_61DN4B5YMREPEZ9C2NM0SE1XTZ/abschluss-nicht-exkl-arzneimittel-rabattvereinb-nach-130a-abs-8-sgb-v-im-wege-ei)  
  Open · SME (from the award notice) · Buyer: AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen · Deadline: 31 Aug 2028, 23:58 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/dc78d638-3c2d-4240-a901-ce7e931a4dca), Last checked 10 Nov 2026, 16:30 (UTC+01:00)
  - Won a contract in CPV group 336 (2026-09-29): [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026
  - Seat in the same country as the place of performance: [Evidence](https://inteliwert.com/company/org_5XF8BQ5ZW1YBVFJ61XGHKYZKK9), checked 10 Nov 2026
  - 2 awards in this field in 36 months, from 2 buyers: [Evidence](https://inteliwert.com/tender/opp_ZFYYHJJ569EAZ7XFM9T1MVY0R4/bekanntmachung-vergebener-auftraege-nach-130-a-abs-8-sgb-v-und-130-c-sgb-v-zu-de), checked 10 Nov 2026

## Is this your company?

Send corrections, or ask us to remove the profile, to <hello@inteliwert.com>. You can also ask that the company never be tagged on LinkedIn.

## About this profile

Each fact on this page shows its source: a public notice, an open-data register (GLEIF, Wikidata) or the company’s own website. Inteliwert does not rate companies and does not judge eligibility, fit or chances.

**Based on the notices and sources Inteliwert covers; not a complete record.** Last checked 29 September 2026.

---

Page: https://inteliwert.com/company/org_5XF8BQ5ZW1YBVFJ61XGHKYZKK9/norgine-gmbh

Inteliwert is a product of Bandpey GmbH, an international data and AI software company in Munich, Germany, founded and led by Roozbeh Bandpey. Bandpey's products: Facthory, Emolysis, Copolly and Inteliwert.

Inteliwert on LinkedIn: https://www.linkedin.com/company/intelliwert, GitHub: https://github.com/inteliwertai.